8 recruiting. 4 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 4 |
| Phase 2 | 4 | Recruiting 4 |
| Phase 3 | 1 | Recruiting 1 |
Follow Synovial Sarcomas: new trials by email Literature Review of Synovial Sarcomas trials Research Report on Synovial Sarcomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine - Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Zelluna Immunotherapy AS | 9 | 2026-05-11 | 2026-09-04 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma TBI-1301, Cyclophosphamide, Fludarabine - Synovial Sarcomas | Phase 3 | Recruiting | Takara Bio Inc. | 5 | 2026-01-05 | 2026-09-28 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Recruiting | Northwestern University | 73 | 2024-09-19 | 2026-10-13 |
| AOH1996 for the Treatment of Refractory Solid Tumors PCNA Inhibitor AOH1996 - Refractory Malignant Solid Neoplasm, Osteosarcoma | Phase 1 | Recruiting | City of Hope Medical Center | 92 | 2022-09-08 | 2026-10-20 |
Sarcoma, Synovial (8) · Leiomyosarcoma (4) · Osteosarcoma (3) · Dermatofibrosarcoma (2) · Histiocytoma, Malignant Fibrous (2) · Liposarcoma (2) · Ovarian Neoplasms (2) · Recurrence (2) · Sarcoma (2) · Adrenal Cortex Neoplasms (1) · Adrenal Gland Neoplasms (1) · Bone Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Ependymoma (1)
Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Connective Tissue (8) · Neoplasms, Connective and Soft Tissue (8) · Sarcoma (6) · Neoplasms by Site (5) · Neoplasms, Muscle Tissue (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms, Bone Tissue (3) · Adnexal Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Disease Attributes (2) · Female Urogenital Diseases (2)
Cyclophosphamide (2) · fludarabine (2) · Quality of Life (1) · Specimen Handling (1) · lutetium Lu 177 dotatate (1) · olaparib (1) · venetoclax (1)
Oslo University Hospital (2) · City of Hope Medical Center (1) · Fundación de investigación HM (1) · Northwestern University (1) · Takara Bio Inc. (1) · Treeline Biosciences, Inc. (1) · Zelluna Immunotherapy AS (1)
Norway (2) · United States (2) · Australia (1) · Japan (1) · Spain (1) · United Kingdom (1)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · Marta Osuna Marco, PhD (1) · Padma Yerramilli-Rao, MB BS, PhD (1) · Pedro Hermida de Viveiros, MD (1) · Vincent Chung, MD (1)
P30CA033572 (1), P30CA060553 (1)